公 告

      阿斯利康自进入中国以来,始终恪守国家相关法律法规,要求全体员工严格遵守国家法律法规和公司规章制度,对任何违法违纪行为坚持零容忍的态度。

      2021年8月,阿斯利康在内部合规检查中发现,深圳市有少数员工存在篡改或参与篡改患者检测报告的行为,涉嫌骗取医保基金。依据合规政策,公司对这些违反公司规章制度的员工进行了严肃的处理,第一时间主动向地方医保部门汇报,表明公司的态度,并积极协助政府调查。

      2021年12月27日,国家医保局和公安部联合约谈阿斯利康中国。会上相关部门介绍了深圳涉嫌骗保案的调查情况,并提出了相关改进意见。公司对此高度重视,诚恳接受国家医保局和公安部门的指导和建议,并将全面落实相关要求,进一步强化管理监督,不断提升员工的法律法规意识,确保将合法合规落实到每位员工的日常工作中。公司将持续开展针对性的内部自查自纠行动,防止任何涉嫌骗保等违法违纪行为的发生。同时,阿斯利康中国将继续不断强化合规文化、合规培训体系和自查自检体系,并加强监管经营活动,确保公司业务在合法合规的前提下可持续地健康开展。

      阿斯利康中国将一如既往地继续深耕中国市场,秉承“患者至上”和“赢之有道”的公司价值观,为广大中国患者提供更多的创新药物。

 

阿斯利康中国

2022年1月

 

###

 

From its inception, AstraZeneca China adheres to PRC laws and regulations and requires all employees to strictly abide by PRC laws and regulations as well as corporate rules and policies. AstraZeneca China sticks to the zero tolerance attitude for any act or conduct that violates laws, regulations, or corporate rules or policies.  

AstraZeneca China confirmed through its own internal compliance investigation in August 2021 that a few of its employees in Shenzhen city had altered or participated in altering patients’ testing reports, and are suspected of committing medical insurance fraud. According to company compliance policy, AstraZeneca China took serious disciplinary action against these employees for violating company policy, proactively reported these offences to the local healthcare security bureau at the earliest possible time to show company’s attitude, and is actively assisting in government investigation.

On December 27, 2021, the National Healthcare Security Administration (NHSA) and the Ministry of Public Security (MOPS) held a joint meeting with AstraZeneca China to brief AstraZeneca China on the investigation of Shenzhen suspected medical insurance fraud and recommended areas for improvement. AstraZeneca China takes such employee misconduct seriously and welcomes the recommendations by the NHSA and MOPS. AstraZeneca China is committed to fully implementing these recommendations, further strengthening management oversight and continuing to educate employees on the applicable laws and regulations, ensuring that each AstraZeneca employee performs daily work with a law abiding and compliance mindset. AstraZeneca China will continue to conduct targeted internal self-inspections and monitor activities to prevent any misuse of public insurance funds or other noncompliance with law or company policy. At the same time, AstraZeneca China will continue strengthening its culture of compliance, its compliance training as well as self-inspection systems and monitoring activities to promote sustainable business development in compliance with laws and regulations.

As always, AstraZeneca China will remain committed to the China market, adhere to our “put patients first” and “do the right thing” values, and provide more innovative drugs to Chinese patients.

 

AstraZeneca China

January 2022